《肺癌靶向治疗研究进展.ppt》由会员分享，可在线阅读，更多相关《肺癌靶向治疗研究进展.ppt（16页珍藏版）》请在三一文库上搜索。
1、晚期非小细胞肺癌EGFR-TKI获得性耐药的热点研究及进展,主要内容：,EGFR-TKI作用机制、耐药机制新药临床研究前景展望,EGFR,ERBB3,AKT,EGFR信号传导的分子机制J,EGFR,GefitinibErlotinib,EGFR-TKI作用机制,主要内容：,EGFR-TKI作用机制、耐药机制新药研究前景展望,EGFR-TKI耐药机制,49%,5%,3%,2%,11%,23%,2%,3%,T790,EGFR,ERBB3,AKT,T790,GefitinibErlotinib,T790M介导EGFR-TKI耐药机制,EGFR-TKI耐药热点研究梳理,EGFR-tki耐药,MET抑制
2、剂,AfatinibDacomitinib,C01686Rociletinib,Rociletinib in EGFR-Mutated NonSmall-Cell Lung Cancer(NCT01526928),N Engl J Med 2015; 372:1700-1709April 30, 2015DOI: 10.1056/NEJMoa1413654,Best Response to Rociletinib:Each bar represents an individual patient, and the amplitude and direction of the bar repre
3、sent the percent change in tumor burden during treatment as compared with baseline. Tumor burden was measured as the sum of thel ongest diameters of the target lesions, according to the Response Evaluation Criteria in Solid Tumors, version 1.1. The dashed line at 20% represents the boundary for dete
4、rmination of progressive disease, and the dashed line at 30% represents the boundary for determination of partial response. FB denotes free base, and HBr hydrogen bromide salt.,Rociletinib in EGFR-Mutated NonSmall-Cell Lung Cancer(NCT01526928),N Engl J Med.2015 Apr 30;372(18):1689-99. doi: 10.1056/N
5、EJMoa1411817.,AZD9291 in EGFR InhibitorResistant NonSmall-CellLung Cancer(NCT01802632),AZD9291,AZD9291 in EGFR InhibitorResistant NonSmall-CellLung Cancer(NCT01802632),AZD9291 in EGFR InhibitorResistant NonSmall-CellLung Cancer(NCT01802632),.,AZD9291 in EGFR InhibitorResistant NonSmall-CellLung Cancer(NCT01802632),前景展望,3代TKI药物应用于耐药的晚期NSCLC患者前景良好。 期临床试验已完成，期待期临床试验结果（目前患者仍在招募中） 。预计23年T790耐药治疗将得到突破。肺癌耐药是一个多靶向、多方向的过程，还将有更长的路要走，期待大家共同完成。,谢谢观赏！,